OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients

Massimo Rugge, Robert M Genta, Matteo Fassan, Elisa Valentini, Irene Coati, Stefano Guzzinati, Edoardo Savarino, Manuel Zorzi, Fabio Farinati, Peter Malfertheiner

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives: Gastritis OLGA-staging ranks the risk for gastric cancer (GC) in progressive stages (0–IV). This long-term follow-up study quantifies the GC risk associated with each OLGA stage. Methods: Consecutive patients (7436) underwent esophagogastroscopy (T-0), with mapped gastric biopsies, OLGA staging, and H. pylori status assessment. Patients with neoplastic lesion (invasive or non-invasive) at the index endoscopy (and/or within 12 months) were excluded. All patients were followed-up (T-1) by combining different sources of clinical/pathological information (Regional Registries of: (i) esophagogastroduodenoscopies; (ii) pathology reports; (iii) cancer, (iv) mortality). The endpoint was histologically documented development of gastric epithelial neoplasia. Results: At T-0, the patients’ distribution by OLGA stage was: Stage 0 = 80.8%; Stage I = 12.6%; Stage II = 4.3%; Stage III = 2.0%; Stage IV = 0.3%; H. pylori infection was detected in 25.9% of patients. At the end of the follow-up (mean/median = 6.3/6.6 years), 28 incident neoplasia were documented (overall prevalence = 0.60 per 103/person-years; low-grade intraepithelial neoplasia = 17/28; high-grade intraepithelial neoplasia = 4/28; GC = 7/28). By OLGA stage at the enrollment, the rate of incident neoplasia was: Stage 0 = 1 case; rate/103 person-years = 0.03; 95%CI: 0.004–0.19; Stage I = 2 cases; rate/103 person-years = 0.34; 95%CI: 0.09–1.36; Stage II = 3 cases; rate/103 person-years = 1.48; 95%CI: 0.48–4.58; Stage III = 17 cases; rate/103 person-years = 19.1; 95%CI: 11.9–30.7; Stage IV = 5 cases; rate/103 person-years = 41.2; 95%CI: 17.2–99.3. Multivariate analysis including gender, age, H. pylori status, and OLGA stage at enrollment only disclosed OLGA stage as predictor of neoplastic progression (OLGA stage III: HR = 712.4, 95%CI = 92.543–5484.5; OLGA stage IV: HR = 1450.7, 95%CI = 166.7–12626.0). Conclusions: Among 7436 patients, OLGA stages at the enrollment correlated significantly with different risk for gastric neoplasia. Based on the obtained results, gastritis staging is a critical adjunct in endoscopy follow-up protocols aimed at GC secondary prevention.

Original languageEnglish (US)
JournalAmerican Journal of Gastroenterology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Gastritis
Stomach Neoplasms
Pylorus
Neoplasms
Stomach
Endoscopy
Digestive System Endoscopy
Secondary Prevention
Registries
Multivariate Analysis
Pathology
Biopsy
Mortality
Infection

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Rugge, M., Genta, R. M., Fassan, M., Valentini, E., Coati, I., Guzzinati, S., ... Malfertheiner, P. (Accepted/In press). OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. American Journal of Gastroenterology. https://doi.org/10.1038/s41395-018-0353-8

OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk : A Long-term Follow-up Study of 7436 Patients. / Rugge, Massimo; Genta, Robert M; Fassan, Matteo; Valentini, Elisa; Coati, Irene; Guzzinati, Stefano; Savarino, Edoardo; Zorzi, Manuel; Farinati, Fabio; Malfertheiner, Peter.

In: American Journal of Gastroenterology, 01.01.2018.

Research output: Contribution to journalArticle

Rugge, M, Genta, RM, Fassan, M, Valentini, E, Coati, I, Guzzinati, S, Savarino, E, Zorzi, M, Farinati, F & Malfertheiner, P 2018, 'OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients', American Journal of Gastroenterology. https://doi.org/10.1038/s41395-018-0353-8
Rugge, Massimo ; Genta, Robert M ; Fassan, Matteo ; Valentini, Elisa ; Coati, Irene ; Guzzinati, Stefano ; Savarino, Edoardo ; Zorzi, Manuel ; Farinati, Fabio ; Malfertheiner, Peter. / OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk : A Long-term Follow-up Study of 7436 Patients. In: American Journal of Gastroenterology. 2018.
@article{dca414e020c64f94a0e555710fb21bcc,
title = "OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients",
abstract = "Objectives: Gastritis OLGA-staging ranks the risk for gastric cancer (GC) in progressive stages (0–IV). This long-term follow-up study quantifies the GC risk associated with each OLGA stage. Methods: Consecutive patients (7436) underwent esophagogastroscopy (T-0), with mapped gastric biopsies, OLGA staging, and H. pylori status assessment. Patients with neoplastic lesion (invasive or non-invasive) at the index endoscopy (and/or within 12 months) were excluded. All patients were followed-up (T-1) by combining different sources of clinical/pathological information (Regional Registries of: (i) esophagogastroduodenoscopies; (ii) pathology reports; (iii) cancer, (iv) mortality). The endpoint was histologically documented development of gastric epithelial neoplasia. Results: At T-0, the patients’ distribution by OLGA stage was: Stage 0 = 80.8{\%}; Stage I = 12.6{\%}; Stage II = 4.3{\%}; Stage III = 2.0{\%}; Stage IV = 0.3{\%}; H. pylori infection was detected in 25.9{\%} of patients. At the end of the follow-up (mean/median = 6.3/6.6 years), 28 incident neoplasia were documented (overall prevalence = 0.60 per 103/person-years; low-grade intraepithelial neoplasia = 17/28; high-grade intraepithelial neoplasia = 4/28; GC = 7/28). By OLGA stage at the enrollment, the rate of incident neoplasia was: Stage 0 = 1 case; rate/103 person-years = 0.03; 95{\%}CI: 0.004–0.19; Stage I = 2 cases; rate/103 person-years = 0.34; 95{\%}CI: 0.09–1.36; Stage II = 3 cases; rate/103 person-years = 1.48; 95{\%}CI: 0.48–4.58; Stage III = 17 cases; rate/103 person-years = 19.1; 95{\%}CI: 11.9–30.7; Stage IV = 5 cases; rate/103 person-years = 41.2; 95{\%}CI: 17.2–99.3. Multivariate analysis including gender, age, H. pylori status, and OLGA stage at enrollment only disclosed OLGA stage as predictor of neoplastic progression (OLGA stage III: HR = 712.4, 95{\%}CI = 92.543–5484.5; OLGA stage IV: HR = 1450.7, 95{\%}CI = 166.7–12626.0). Conclusions: Among 7436 patients, OLGA stages at the enrollment correlated significantly with different risk for gastric neoplasia. Based on the obtained results, gastritis staging is a critical adjunct in endoscopy follow-up protocols aimed at GC secondary prevention.",
author = "Massimo Rugge and Genta, {Robert M} and Matteo Fassan and Elisa Valentini and Irene Coati and Stefano Guzzinati and Edoardo Savarino and Manuel Zorzi and Fabio Farinati and Peter Malfertheiner",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41395-018-0353-8",
language = "English (US)",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk

T2 - A Long-term Follow-up Study of 7436 Patients

AU - Rugge, Massimo

AU - Genta, Robert M

AU - Fassan, Matteo

AU - Valentini, Elisa

AU - Coati, Irene

AU - Guzzinati, Stefano

AU - Savarino, Edoardo

AU - Zorzi, Manuel

AU - Farinati, Fabio

AU - Malfertheiner, Peter

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: Gastritis OLGA-staging ranks the risk for gastric cancer (GC) in progressive stages (0–IV). This long-term follow-up study quantifies the GC risk associated with each OLGA stage. Methods: Consecutive patients (7436) underwent esophagogastroscopy (T-0), with mapped gastric biopsies, OLGA staging, and H. pylori status assessment. Patients with neoplastic lesion (invasive or non-invasive) at the index endoscopy (and/or within 12 months) were excluded. All patients were followed-up (T-1) by combining different sources of clinical/pathological information (Regional Registries of: (i) esophagogastroduodenoscopies; (ii) pathology reports; (iii) cancer, (iv) mortality). The endpoint was histologically documented development of gastric epithelial neoplasia. Results: At T-0, the patients’ distribution by OLGA stage was: Stage 0 = 80.8%; Stage I = 12.6%; Stage II = 4.3%; Stage III = 2.0%; Stage IV = 0.3%; H. pylori infection was detected in 25.9% of patients. At the end of the follow-up (mean/median = 6.3/6.6 years), 28 incident neoplasia were documented (overall prevalence = 0.60 per 103/person-years; low-grade intraepithelial neoplasia = 17/28; high-grade intraepithelial neoplasia = 4/28; GC = 7/28). By OLGA stage at the enrollment, the rate of incident neoplasia was: Stage 0 = 1 case; rate/103 person-years = 0.03; 95%CI: 0.004–0.19; Stage I = 2 cases; rate/103 person-years = 0.34; 95%CI: 0.09–1.36; Stage II = 3 cases; rate/103 person-years = 1.48; 95%CI: 0.48–4.58; Stage III = 17 cases; rate/103 person-years = 19.1; 95%CI: 11.9–30.7; Stage IV = 5 cases; rate/103 person-years = 41.2; 95%CI: 17.2–99.3. Multivariate analysis including gender, age, H. pylori status, and OLGA stage at enrollment only disclosed OLGA stage as predictor of neoplastic progression (OLGA stage III: HR = 712.4, 95%CI = 92.543–5484.5; OLGA stage IV: HR = 1450.7, 95%CI = 166.7–12626.0). Conclusions: Among 7436 patients, OLGA stages at the enrollment correlated significantly with different risk for gastric neoplasia. Based on the obtained results, gastritis staging is a critical adjunct in endoscopy follow-up protocols aimed at GC secondary prevention.

AB - Objectives: Gastritis OLGA-staging ranks the risk for gastric cancer (GC) in progressive stages (0–IV). This long-term follow-up study quantifies the GC risk associated with each OLGA stage. Methods: Consecutive patients (7436) underwent esophagogastroscopy (T-0), with mapped gastric biopsies, OLGA staging, and H. pylori status assessment. Patients with neoplastic lesion (invasive or non-invasive) at the index endoscopy (and/or within 12 months) were excluded. All patients were followed-up (T-1) by combining different sources of clinical/pathological information (Regional Registries of: (i) esophagogastroduodenoscopies; (ii) pathology reports; (iii) cancer, (iv) mortality). The endpoint was histologically documented development of gastric epithelial neoplasia. Results: At T-0, the patients’ distribution by OLGA stage was: Stage 0 = 80.8%; Stage I = 12.6%; Stage II = 4.3%; Stage III = 2.0%; Stage IV = 0.3%; H. pylori infection was detected in 25.9% of patients. At the end of the follow-up (mean/median = 6.3/6.6 years), 28 incident neoplasia were documented (overall prevalence = 0.60 per 103/person-years; low-grade intraepithelial neoplasia = 17/28; high-grade intraepithelial neoplasia = 4/28; GC = 7/28). By OLGA stage at the enrollment, the rate of incident neoplasia was: Stage 0 = 1 case; rate/103 person-years = 0.03; 95%CI: 0.004–0.19; Stage I = 2 cases; rate/103 person-years = 0.34; 95%CI: 0.09–1.36; Stage II = 3 cases; rate/103 person-years = 1.48; 95%CI: 0.48–4.58; Stage III = 17 cases; rate/103 person-years = 19.1; 95%CI: 11.9–30.7; Stage IV = 5 cases; rate/103 person-years = 41.2; 95%CI: 17.2–99.3. Multivariate analysis including gender, age, H. pylori status, and OLGA stage at enrollment only disclosed OLGA stage as predictor of neoplastic progression (OLGA stage III: HR = 712.4, 95%CI = 92.543–5484.5; OLGA stage IV: HR = 1450.7, 95%CI = 166.7–12626.0). Conclusions: Among 7436 patients, OLGA stages at the enrollment correlated significantly with different risk for gastric neoplasia. Based on the obtained results, gastritis staging is a critical adjunct in endoscopy follow-up protocols aimed at GC secondary prevention.

UR - http://www.scopus.com/inward/record.url?scp=85055095882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055095882&partnerID=8YFLogxK

U2 - 10.1038/s41395-018-0353-8

DO - 10.1038/s41395-018-0353-8

M3 - Article

C2 - 30333540

AN - SCOPUS:85055095882

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

ER -